Fundraising Fox

Vivace Therapeutics

San Mateo, US · Founded 2014 · Delaware corporation · 4 known investors

vivacetherapeutics.com ↗

Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.

BiotechHealthtechMedical Devices

Founders & leadership

EH
Edward HuDirector
JW
Jun WuDirector
JS
Jake SimsonDirector
CZ
Chenguang ZhouDirector
SQ
Shuang QiaoExecutive Officer, Director
SD
Sheng DingExecutive Officer
TS
Tim ShannonDirector

Investors · 4

Canaan Partners✓ verifiedStamford · $500K – $20Mvia Tim Shannon · board
RA Capital✓ verifiedBoston
Cenova CapitalShanghai
Mission BiocapitalSan Francisco · $500K

Reported raises · per SEC filings

Form D private placements
▶$17.5MraisedMar 2025 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward HuDirector
  • Jun WuDirector
  • Jake SimsonDirector
  • Tim ShannonDirector
  • Chenguang ZhouDirector
  • Shuang QiaoExecutive Officer, Director
Offering amount
$35M
Amount sold
$17.5M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedDec 2020 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shuang QiaoExecutive Officer, Director
  • Edward HuDirector
  • Leonard PostDirector
  • Tim ShannonDirector
  • Jun WuDirector
  • Chenguang ZhouDirector
Offering amount
$30M
Amount sold
$30M
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedMay 2018 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Leonard PostExecutive Officer, Director
  • Shuang QiaoExecutive Officer, Director
  • Edward HuDirector
  • Tim ShannonDirector
  • Jun WuDirector
Offering amount
$25M
Amount sold
$8M
First sale
May 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJan 2015 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Shuang QiaoExecutive Officer, Director
  • Edward HuDirector
  • Tim ShannonDirector
  • Sheng DingExecutive Officer
Offering amount
$15.1M
Amount sold
$5M
First sale
Jan 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news